REGENEUS has been given approval for a US patent for its osteoarthritis cell therapy Progenza.
The ASX-listed company confirmed yesterday it had been issued with a notice of allowance for issuance of a patent covering the composition and use of Progenza, which will provide commercial rights in the US through to 2032.
Corresponding patents have been granted in Australia and Japan and are being pursued in other key territories including Europe.
Progenza is made from expanded allogeneic mesenchymal stem cells (MSCs) from human adipose tissue and contains the bioactive secretions of the cells.
Regeneus says in addition to osteoarthritis and other musculoskeletal diseases, Progenza has potential to be used for other inflammatory diseases.